Skip to content

Trigger Point Injections for Post-Mastectomy Pain Syndrome

Trigger Point Injections for Post-Mastectomy Pain Syndrome: A Double-Blind Randomized Controlled Trial With Intention-to-Treat Analysis

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04267315
Enrollment
72
Registered
2020-02-12
Start date
2020-01-03
Completion date
2024-02-15
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Myofascial Pain Syndrome, Post-mastectomy Pain Syndrome, Trigger Point Pain, Myofascial

Brief summary

Post-Mastectomy Pain Syndrome (PMPS) is a chronic pain that persists for more than three months after a surgical breast procedure. It has 11-70% incidence in patients that underwent a breast surgery. It consists of mixed pain, frequently associated with myofascial pain, an specific type of muscular pain. Trigger point injections (TPI) are classically used for the treatment of myofascial pain in other painful conditions. However, there are no controlled trials assessing the efficacy of TPI in the treatment of PMPS. The intervention objective is to assess the efficacy of TPI in patients with PMPS, when associated with a comprehensive rehabilitation program and pain management.

Detailed description

INTRODUCTION: Post-Mastectomy Pain Syndrome (PMPS) is a chronic pain that persists for more than three months after a surgical breast procedure. It has 11-70% incidence in patients that underwent a breast surgery. It consists of mixed pain, frequently associated with myofascial pain. Trigger point injections (TPI) are classically used for the treatment of myofascial pain in other etiologies. However, there are no controlled trials assessing the efficacy of TPI in the treatment of PMPS OBJECTIVE: Assess the efficacy of TPI in patients with PMPS, when associated with a comprehensive rehabilitation program and pain management. METHODS: Double-blind randomized controlled trial with intention-to-treat analysis. Both groups will undergo standard of care delivered by Physiatrist blinded to group allocation. Active group will undergo TPI with 1% lidocaine in each identified trigger-point, weekly, for three consecutive weeks. Control group will undergo subcutaneous saline injection superficial to the same trigger points, with the same frequency and number of sessions. Primary outcome is the mean difference between groups for pain levels, as assessed by Visual Numeric Scale (VNS), from baseline to 3 months after the procedure. STATISTICAL ANALYSIS: Difference between groups at baseline, one and three months after injection, using Analysis of Covariance (ANCOVA) for the following outcomes: VNS; Presence of active trigger points, Pressure pain threshold (PPT); Short-Form McGill Pain Questionnaire (SF-MPQ); Neuropathic Pain Symptom Inventory (NPSI); Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH); Range of motion (ROM) of affected shoulder, for abduction and external rotation; adverse events; use of pain medication. Total sample size is 120. Alpha=5%, power=80%.

Interventions

1mL injections of 1% lidocaine in the muscles identified active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).

PROCEDURESubcutaneous saline injection

0.2mL subcutaneous saline injections superficial to the muscles identified with active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).

Patients in both groups will undergo standard of care rehabilitation delivered by a Physiatrist, which may include Physical Therapy, Occupational Therapy, Exercise Physiologist, Rehabilitation Nurse, Psychologist, as per Physiatrist's prescription. Both the comprehensive rehabilitation program and pain medications will continue to be managed by participant's Physiatrist, who will be blinded to patient's allocation. The researchers will be responsible for TPI and for data collection.

Sponsors

Hospital de Câncer de Barretos
CollaboratorOTHER
Instituto do Cancer do Estado de São Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Patients will be randomized as they enter the study (T0). Only one of the researchers will have access to the randomization list. The researcher responsible for the procedure will receive an email at the day of the first injection, informing of the participant's allocation group. The outcomes assessor, patient, attending Physiatrist and the Rehabilitation team will be blinded to the patient's allocation group until the end of the study. Only the researcher the performed the TPI, and the researcher responsible for the allocation list will have access to that information.

Intervention model description

Double-blind randomized controlled trial comparing the efficacy of TPI + standard of care (ACTIVE) versus sham TPI + standard of care(PLACEBO), with an intention-to-treat analysis

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Breast cancer patients. * PMPS diagnosis, as per Wisotzky et col. * Pain \> 3 months over breast, chest wall or shoulder ipsilateral to surgery. * Pain Visual analog Scale (VAS) ≥4. * At least one active trigger point in the following muscles: pectoralis major, superior trapezius, serratus anterior, levator scapularis, latissimus dorsi, infraspinatus

Exclusion criteria

* Current radiation therapy or time since completion \< 3months. * Allergy to lidocaine or other local anesthetics * Active infection over injection sites * Unavailability to be at the hospital during study intervention.

Design outcomes

Primary

MeasureTime frameDescription
Visual Numeric Scale (VNS) for pain in 3 months3 monthsMean difference of Pain between groups from baseline to 3 months(T3m), assessed by the Visual Numeric Scale (VNS, 0-10), in which higher scores represent higher pain intensity.
Trigger-points1 monthNumber of active trigger-points in the assessed muscles (latissimus dorsi, levator scapulae, trapezius superior, infraspinatus, pectoralis major, serratus anterior). Mean difference between groups.
Pressure Pain Threshold (PPT)1 monthPressure Pain Threshold (PPT) at bilateral latissimus dorsi, levator scapulae, trapezius superior, infraspinatus, pectoralis major, serratus anterior. Difference from baseline
Pressure Pain Threshold3 monthsPressure Pain Threshold (PPT) at bilateral latissimus dorsi, levator scapulae, trapezius superior, infraspinatus, pectoralis major, serratus anterior. Difference from baseline

Secondary

MeasureTime frameDescription
Shoulder range of motion (ROM)1 monthRange of motion (ROM) of affected shoulder, for abduction and external rotation. Mean difference between groups from baseline.
Percentage of patients with at least 30% improvement of pain as per VNS scores (VNS30%)1 monthPercentage of patients with at least 30% improvement of pain as per VAS scores (VAS30%). Mean difference between groups.
Visual Numeric Scale (VNS) for pain in 1 month1 monthMean difference of Pain between groups from baseline,assessed by the Visual Numeric Scale (VNS, 0-10), in which higher scores represent higher pain intensity.
Adverse events1 monthNumber of participants with adverse events. Mean difference between groups.
Pain medication1 monthsUse of pain medication. Classified as Increased, Decreased, Stable or Non-applicable . Mean difference between groups.
Percentage of patients with at least 50% improvement of pain as per VNS scores (VNS50%)1 monthPercentage of patients with at least 50% improvement of pain as per VAS scores (VAS30%). Mean difference between groups.
Short-Form McGill Pain Questionnaire (SF-MPQ) - total score, sensorial and affective scale1 monthShort-Form McGill Pain Questionnaire - total score, sensorial and affective scale. Mean difference between groups from baseline. Higher values represent higher pain intensity
Neuropathic Pain Symptom Inventory (NPSI)1 month.Neuropathic Pain Symptom Inventory . Mean difference between groups from baseline. Higher values represent more symptoms of neuropathic pain.
Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH)1 monthDisabilities of the Arm, Shoulder and Hand Questionnaire (DASH). Mean difference between groups from baseline. Higher values represent lower functionality.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026